Chemistry: analytical and immunological testing – Involving immune complex formed in liquid phase
Patent
1994-12-06
1997-08-19
Budens, Robert D.
Chemistry: analytical and immunological testing
Involving immune complex formed in liquid phase
435 7021, 435335, 436548, 53038824, 5303913, 53038823, G01N 33536, C07K 1622, C07K 1624, C12N 520
Patent
active
056588038
ABSTRACT:
Cell lines are provided that produce improved neutralizing monoclonal antibodies reactive with human cachectin. The antibodies have various therapeutic and diagnostic uses.
REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4684623 (1987-08-01), Larrick et al.
patent: 4834976 (1989-05-01), Rosok et al.
patent: 4870163 (1989-09-01), Rubin et al.
patent: 5231024 (1993-07-01), Moeller et al.
Pennica, et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin," Nature (1984), 312:724-728.
Shirai, et al., "Cloning and Expression in E. Coli of the Gene for Human Tumour Necrosis Factor," Nature (1985), 313:803-806.
Beutler, et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," Science (1985), 229:869-871.
Liang, et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," Biochem. Biophys. Res. Comm. (1986) 137:847-854.
Fendly, et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," Hybridoma (1987) 6:359-370.
Hirai, et al., "Production and Characterization of Monoclonal Antibodies to Human Tumor Necrosis Factor," J. Immunol. Meth. (1987) 96:57-62.
Beutler, et al., "Cachectin: More Than A Tumor Necrosis Factor," New Eng. J. Med. (1987), 316:379-385.
Tsujimoto, et al., "Comparative Studies of the Biological Activities of Human Tumor Necrosis Factor and Its Derivatives," J. Biochem. (1987), 101:919-925.
Tracey, et al., "Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia," Nature (1987) 330:662-664.
Mathison, et al., "Participation of Tumor Necrosis Factor in the Mediation of Gram Negative Bacterial Lipopolysaccharide-Induced Injury in Rabbits," J. Clin. Invest. (1988), 81:1925-1937.
Michie, et al., "Detection of Circulating Tumor Necrosis Factor After Endotoxin Administration," New Eng. J. Med. (1988) 318:1481-1486.
Hinshaw, et al., "Current Management of the Septic Shock Patient: Experimental Basis for Treatment," Circulatory Shock (1982) 9:543-553.
Waldmann, T.A., "Monoclonal Antibodies in Diagnosis and Therapy," Science 252: 1657-1662, 21 Jun. 1991.
Fitzer-Schiller, G., "Centocor Stops Trials of Flagship Drug," Washington Post, 19 Jan. 1993.
Harris et al, "Therapeutic Antibodies--The Coming of Age", Trends in Biotechnology 11:42-44, Feb. 1993.
Abramowicz, D., et al., "Anaphylactic Shock After Treatment With OKT3 Monoclonal Antibody", New England J. Med., 3 Sep. 1992, p. 736.
Cross et al., "Choice of Bacteria in Animal Models of Sepsis," Infection and Immunity 61(7):2741-2747, Jul. 1993.
Hesse et al., "Cytokine Appearance in Human Endotoxemia and Primate Bacteremia," Surg. Gynecol. Obstet. 166(2):147-153, 1988.
Blackburn Robert P.
Budens Robert D.
Chiron Corporation
Robins Roberta L.
Savereide Pauul B.
LandOfFree
Monoclonal antibodies reactive with cachectin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies reactive with cachectin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies reactive with cachectin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1104331